

BIOLASE, INC  
Form 8-K/A  
February 05, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

January 31, 2015

**Biolase, Inc.**

\_\_\_\_\_  
(Exact name of registrant as specified in its charter)

Delaware

000-19627

87-0442441

\_\_\_\_\_  
(State or other jurisdiction  
of incorporation)

\_\_\_\_\_  
(Commission  
File Number)

\_\_\_\_\_  
(I.R.S. Employer  
Identification No.)

4 Cromwell, Irvine, California

92618

\_\_\_\_\_  
(Address of principal executive offices)

\_\_\_\_\_  
(Zip Code)

Registrant's telephone number, including area code:

949-361-1200

Not Applicable

\_\_\_\_\_  
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Top of the Form**

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On February 5, 2015, Biolase, Inc. (the "Company") reported on a Current Report on Form 8-K (the "February 5, 2015 Form 8-K") that, effective January 31, 2015, Frederick D. Furry resigned from his position with the Company. This amendment is to clarify a typographical error made in the February 5, 2015 Form 8-K. The Company entered into a Separation Agreement with General Release of all Claims with Mr. Furry on January 31, 2015.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

*February 5, 2015*

Biolase, Inc.

By: */s/ Jeffrey M. Nugent*

---

*Name: Jeffrey M. Nugent*

*Title: President and Chief Executive Officer*